Compare XOMA & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XOMA | REFI |
|---|---|---|
| Founded | 1981 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.6M | 255.6M |
| IPO Year | N/A | 2021 |
| Metric | XOMA | REFI |
|---|---|---|
| Price | $27.59 | $12.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $60.60 | $20.00 |
| AVG Volume (30 Days) | ★ 134.0K | 121.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 16.79% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $48,857,628.00 |
| Revenue This Year | $76.93 | $13.69 |
| Revenue Next Year | $29.28 | $3.55 |
| P/E Ratio | $29.64 | ★ $9.43 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.40 | $11.62 |
| 52 Week High | $39.92 | $16.15 |
| Indicator | XOMA | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 54.88 |
| Support Level | $23.92 | $12.23 |
| Resistance Level | $35.17 | $12.49 |
| Average True Range (ATR) | 1.47 | 0.24 |
| MACD | 0.26 | 0.05 |
| Stochastic Oscillator | 97.87 | 86.79 |
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.